⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2080425 | 0.82 | — | — | |
| SCHEMBL28422285 | 0.74 | — | — | |
| SCHEMBL8676219 | 0.73 | — | — | |
| SCHEMBL1697572 | 0.71 | — | — | |
| SCHEMBL2432093 | 0.69 | — | — | |
| SCHEMBL9925351 | 0.67 | — | — | |
| SCHEMBL29219048 | 0.67 | — | — | |
| SCHEMBL29143695 | 0.67 | — | — | |
| SCHEMBL11063397 | 0.67 | — | — | |
| SCHEMBL21526281 | 0.65 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1404325-A2 | METHOD FOR TREATING NERVE INJURY CAUSED BY SURGERY | GUILFORD PHARMACEUTICALS INC. (US) | 2004-04-07 | — | — | EP | disclosed |
| WO-2002096420-A2 | METHOD FOR TREATING NERVE INJURY CAUSED BY SURGERY | GUILFORD PHARMACEUTICALS INC. (US) | 2002-12-05 | — | — | WO | disclosed |
| EP-1127049-A1 | BRIDGED HETEROCYCLIC DERIVATIVES | GPI NIL Holdings, Inc. (US) | 2001-08-29 | — | — | EP | disclosed |
| EP-1107754-A1 | UREAS AND CARBAMATES OF N-HETEROCYCLIC CARBOXYLIC ACIDS AND ISOSTERES FOR VISION AND MEMORY DISORDERS | GPI NIL Holdings, Inc. (US) | 2001-06-20 | — | — | EP | disclosed |
| EP-1105124-A2 | N-LINKED SULFONAMIDES OF N-HETEROCYCLIC CARBOXYLIC ACIDS OR ISOSTERES FOR VISION AND MEMORY DISORDERS | GPI NIL Holdings, Inc. (US) | 2001-06-13 | — | — | EP | disclosed |
| EP-1102756-A1 | AZA-HETEROCYCLIC COMPOUNDS USED TO TREAT NEUROLOGICAL DISORDERS AND HAIR LOSS | GPI NIL Holdings, Inc. (US) | 2001-05-30 | — | — | EP | disclosed |
| EP-1084107-A1 | AZA-HETEROCYCLIC COMPOUNDS USED TO TREAT NEUROLOGICAL DISORDERS AND HAIR LOSS | GPI NIL Holdings, Inc. (US) | 2001-03-21 | — | — | EP | disclosed |
| EP-1082301-A1 | UREAS AND CARBAMATES OF N-HETEROCYCLIC CARBOXYLIC ACIDS AND CARBOXYLIC ACID ISOSTERES | GPI NIL Holdings, Inc. (US) | 2001-03-14 | — | — | EP | disclosed |
| EP-1011650-A1 | METHOD FOR PREVENTING AND TREATING HEARING LOSS USING SENSORINEUROTROPHIC COMPOUNDS | Amgen Inc., (US) | 2000-06-28 | — | — | EP | disclosed |
| WO-2000009103-A9 | N-LINKED SULFONAMIDES OF N-HETEROCYCLIC CARBOXYLIC ACIDS OR ISOSTERES FOR VISION AND MEMORY DISORDERS | GUILFORD PHARM INC (US) | 2000-06-08 | — | — | WO | disclosed |
| WO-2000016603-A2 | BRIDGED HETEROCYCLIC DERIVATIVES | GPI NIL HOLDINGS, INC. (US) | 2000-03-30 | — | — | WO | disclosed |
| WO-2000009103-A2 | N-LINKED SULFONAMIDES OF N-HETEROCYCLIC CARBOXYLIC ACIDS OR ISOSTERES FOR VISION AND MEMORY DISORDERS | GPI NIL HOLDINGS, INC. (US) | 2000-02-24 | — | — | WO | disclosed |
| WO-2000009125-A1 | UREAS AND CARBAMATES OF N-HETEROCYCLIC CARBOXYLIC ACIDS AND ISOSTERES FOR VISION AND MEMORY DISORDERS | GPI NIL HOLDINGS, INC. (US) | 2000-02-24 | — | — | WO | disclosed |
| WO-1999062888-A1 | AZA-HETEROCYCLIC COMPOUNDS USED TO TREAT NEUROLOGICAL DISORDERS AND HAIR LOSS | GPI NIL HOLDINGS, INC. (US) | 1999-12-09 | — | — | WO | disclosed |
| WO-1999062879-A1 | UREAS AND CARBAMATES OF N-HETEROCYCLIC CARBOXYLIC ACIDS AND CARBOXYLIC ACID ISOSTERES | GPI NIL HOLDINGS, INC. (US) | 1999-12-09 | — | — | WO | disclosed |
| WO-1999062881-A1 | AZA-HETEROCYCLIC COMPOUNDS USED TO TREAT NEUROLOGICAL DISORDERS AND HAIR LOSS | GPI NIL HOLDINGS, INC. (US) | 1999-12-09 | — | — | WO | disclosed |
| WO-1999014998-A2 | METHOD FOR PREVENTING AND TREATING HEARING LOSS USING SENSORINEUROTROPHIC COMPOUNDS | AMGEN INC. (US) | 1999-04-01 | — | — | WO | disclosed |